Maxim Group analyst Anthony Vendetti has reiterated their bullish stance on SRTS stock, giving a Buy rating yesterday.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Anthony Vendetti has given his Buy rating due to a combination of factors, including Sensus Healthcare’s strong performance in the first quarter of 2025, where the company exceeded revenue expectations despite lower earnings per share. The company’s strategic shift towards the ‘Fair Deal’ program, which is expected to drive growth through increased device installations and utilization, is a significant factor in this rating.
Additionally, Sensus Healthcare’s financial health, with a substantial cash reserve and no debt, positions it well for future growth opportunities, particularly in acquisitions. The anticipated approval of the TransDermal Infusion (TDI) 510(k) application by the third quarter of 2025 is also seen as a potential growth catalyst. Despite lowering revenue and earnings estimates and reducing the price target, the continued momentum in device placements and the expansion of the ‘Fair Deal’ program support the Buy rating.
In another report released yesterday, H.C. Wainwright also reiterated a Buy rating on the stock with a $12.00 price target.